Table 3. Distribution of the patients according to their haematologic and cytogenetic response at the time of disease resistance.

	CHR	PHR	No HR	CCyR	Partial CyR	Minor CyR	Minimal CyR	No CyR	Total
	n/N(%)	n/N(%)	n/N(%)	n/N(%)	n/N(%)	n/N(%)	n/N(%)	n/N(%)
CP	9/46	16/23	4/13	1/3	4/29	7/18	9/16	8/10	29/76
AP	1/4	2/2	2/3	0/0	0/2	1/2	2/2	2/3	5/9
BC	0/0	1/2	6/7	0/0	2/2	1/1	1/1	3/5	7/9

Frequency of mutations in patients with Haematologic resistance: 31/50 (62%)

Frequency of mutations in patients with cytogenetic resistance: 39/91 (43%)

CP: Chronic Phase

AP: Accelerated Phase

BC: Blast Crisis

CHR: complete Haematologic Response

CCyR: Complete Cytogenetic Response

n: Number of patients with mutations

N: Number of imatinib resistant patients